Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
AEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Adient has the footprint OEMs need and the revenue scale investors notice, but the stock case comes down to whether EMEA repair, Asia pricing, launch costs, tariffs, and working capital finally let margin catch up with sales.
OpenACV just paired record Q1 revenue and improving adjusted EBITDA with GAAP losses, $200 million of debt, big receivable balances, and a $50 million accelerated repurchase. The tension is not whether the marketplace is real; it is whether the economics can becom
OpenAchieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.
OpenTag facets appear after tag usage counts are rebuilt.